01:56:39 EDT Tue 19 Mar 2024
Enter Symbol
or Name
USA
CA



Rise Life Science Corp
Symbol RLSC
Shares Issued 43,998,340
Close 2018-04-24 C$ 0.325
Market Cap C$ 14,299,461
Recent Sedar Documents

Rise Life Science commissions study on pot and sex

2018-04-24 10:09 ET - News Release

Mr. Anton Mattadeen reports

RISE LIFE SCIENCE CORP. ANNOUNCES THE RISE REPORT: A STUDY TO EXPLORE CANNABIS USE AND SEXUAL HEALTH

Rise Life Science Corp. has commissioned a longitudinal study to investigate sexual function and health concerns, and, how cannabis products designed for sexual enhancement and health affect sexual behaviours and performance. The Rise report on cannabis and sexual health and wellness will be significant in its long-term open-ended focus, overall scope and the value of the data it is designed to capture.

Dr. Regina Nelson, a behavioural scientist and one of America's leading cannabis educators, will lead the study. Dr. Nelson is supported in these efforts by Dr. Christopher J. Smith, a social science expert, and Dr. Jon Ross, a health care and public policy expert.

"As cannabis evolves into widespread medical and mainstream commercial use, the benefits of cannabis products and their relation to sexual health are particularly important to every stakeholder, from public health officials to companies making cannabis-based products, and especially for the general consumer," commented Dr. Nelson, study designer and principal researcher.

"To date, no scholarly investigation of the physiological connection between cannabis and sexual health has ever been undertaken at this scale. This study presents the opportunity to expand our collective knowledge, increase our understanding and create a critically important data set regarding sexual behaviour, health and wellness."

"We are investing in this study because it is central to the ongoing development of consumer products that individuals and couples believe in and actually want to use," said Anton Mattadeen, chief executive officer of Rise Life Science. "The proprietary data generated by this study will not only add necessary information to the subject of sexual health, it will also inform Rise of the best possible product development decisions to meet the needs of our customers, provide us with a competitive advantage in the marketplace and help us remain right in the middle of this important conversation with our expanding consumer community."

The study and key facts

  • Clear purpose: This is a long-term observational study collecting quantitative and qualitative data, exploring cannabis usage as an aid for sexual performance and collection of experiential data related to the use of Rise sexual health and wellness products.
  • No gender bias: The company will look at specific differences in effect across genders, as its study will extend beyond heterosexual participants.
  • Real user experiences: In addition to clinical and statistical data, the Rise study will collect consumer stories and experiences.
  • Important observations: The study will focus on many critical areas in need of review:
    • Emotional and physical satisfaction with and without a partnered sexual relationship;
    • Satisfaction with sexual health and function;
    • The importance of sex, sexual function and health to quality of life;
    • How introducing novel cannabis products designed for sexual enhancement and health affect sexual experiences.
  • Usage mode profiles: Research will range beyond smoking and vaping and include other important forms of consumption such as oral sprays, oils, concentrates, edibles and topical solutions.
  • Anonymity and security: Given the topic and increasing privacy concerns, the company is protecting personally identifiable information by simply not collecting it at all. This is a strictly anonymous study, with rich profile data and outcomes directly related to cannabis product use.

The study is expected to initially enroll approximately 200 participants during its beta test phase starting in the spring of 2018, with the official study launch tentatively scheduled for September of 2018. As the study continues to expand over time, the long-term goal is to engage with thousands of participants.

About Dr. Nelson

Dr. Nelson is a published author of several books, and earned her PhD in ethical and creative leadership at Union Institute and University. Her doctoral studies concentrate on the issue of medical cannabis. In 2012, Dr. Nelson published her first peer-reviewed article, Framing Integral Leadership within the Medical Cannabis Community. She has gone on to publish and present in 20 peer-reviewed forums, including events hosted by the International Leadership Association, the International Cannabinoid Research Society and the Integral European Conference. In addition to her role as chief executive officer of Integral Education and Consulting LLC, she is also a founding officer of the eCS Therapy Center, an Integral 501C3 organization building awareness of the endocannabinoid system (eCS) and championing community-based education via the Plant a Seed for Cannabis Education Tour.

About Rise Life Science Corp.

Rise Life Science develops cutting-edge cannabis consumer products for both medical and adult-use markets around the world in jurisdictions that have legal regulatory frameworks in place. All products are based on patent-pending formulations and processes to produce specifically targeted effects. A key area of focus for Rise is research-based formulations to address adult sexual health and wellness for both women and men.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.